ASH/ISTH 2026 儿童静脉血栓栓塞症风险患者抗凝预防指南
该指南由美国血液学会(ASH)与国际血栓与止血学会(ISTH)联合制定,采用GRADE方法系统评价截至2025年4月的证据,共形成12条推荐。对于实体瘤、创伤或危重患儿,面板条件性建议不进行抗凝预防;对于抗磷脂抗体综合征或长期全肠外营养患儿,条件性建议使用抗凝预防。其他亚组包括急性淋巴细胞白血病或淋巴瘤、手术及住院患儿、中心静脉通路装置患儿。高质量证据稀缺,关键研究方向包括开发验证亚组特异性VTE风险评估模型及评价风险分层抗凝预防策略的安全性和有效性。
要点
- 实体瘤、创伤或危重患儿:条件性建议不进行抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
- 抗磷脂抗体综合征或长期全肠外营养患儿:条件性建议使用抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
- 指南共形成12条推荐,覆盖急性淋巴细胞白血病/淋巴瘤、手术、住院及中心静脉通路装置等亚组。
- 儿童VTE抗凝预防高质量数据稀缺,亚组特异性风险评估模型尚待开发验证。
适用人群与场景
- 住院患儿及患有慢性疾病的儿童,具体亚组包括实体瘤、创伤、危重患儿、抗磷脂抗体综合征、长期全肠外营养、急性淋巴细胞白血病或淋巴瘤、手术患儿、住院患儿及中心静脉通路装置患儿。
处置流程与药物剂量
- 实体瘤患儿:条件性建议不进行抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
- 创伤患儿:条件性建议不进行抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
- 危重患儿:条件性建议不进行抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
- 抗磷脂抗体综合征患儿:条件性建议使用抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
- 长期全肠外营养患儿:条件性建议使用抗凝预防(ASH/ISTH 2026,GRADE条件性推荐)。
研究设计与关键结果
- ASH成立多学科指南面板(含1名患者代表),堪萨斯大学卫生系统支持指南制定,系统证据评价截至2025年4月,采用GRADE方法评估证据确定性并形成推荐,共达成12条推荐。
- 对实体瘤、创伤或危重患儿,面板条件性建议不进行抗凝预防;对抗磷脂抗体综合征或长期全肠外营养患儿,条件性建议使用抗凝预防。
- 其他涉及的亚组包括急性淋巴细胞白血病或淋巴瘤、手术及住院患儿、中心静脉通路装置患儿。
证据类型、等级与局限
- 证据类型:指南(ASH/ISTH),采用GRADE方法评估证据确定性和推荐强度。
- 推荐强度:条件性推荐(conditional recommendations)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于实体瘤、创伤或危重患儿,依据ASH/ISTH 2026指南条件性建议不进行抗凝预防,避免不必要的抗凝暴露。
- 对于抗磷脂抗体综合征或长期全肠外营养患儿,依据ASH/ISTH 2026指南条件性建议使用抗凝预防。
- 指南强调儿童VTE抗凝预防高质量数据稀缺,亚组特异性风险评估模型尚待开发验证,临床决策需结合个体情况。
指南或共识出处
- ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism(美国血液学会/国际血栓与止血学会,2026年)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: High-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.
BACKGROUND: Venous thromboembolism (VTE) is a significant cause of morbidity in children, particularly among hospitalized patients and those with chronic medical conditions. There is a lack of consensus on anticoagulant prophylaxis strategies.
OBJECTIVE: These evidence-based guidelines from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients and health care professionals in decisions about anticoagulant prophylaxis for pediatric VTE prevention.
METHODS: ASH formed a multidisciplinary guideline panel that included 1 patient representative. The University of Kansas Health System supported the guideline development process, including systematic evidence reviews up to April 2025. Clinical questions and outcomes were prioritized according to their importance for clinicians and patients. The panel used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to assess certainty in the evidence and make recommendations.
RESULTS: The panel agreed on 12 recommendations. For pediatric patients with solid cancer, who have experienced trauma, or who are critically ill, the panel issued conditional recommendations suggesting no anticoagulant prophylaxis. For pediatric patients with antiphospholipid antibody syndrome, or those on long-term total parenteral nutrition, the panel issued conditional recommendations suggesting the use of anticoagulant prophylaxis. Other pediatric subgroups addressed included patients with acute lymphoblastic leukemia or lymphoma, surgical and hospitalized patients, and those with a central venous access device.
CONCLUSIONS: High-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.
参考来源
- Betensky M, Azzam M, Bercovitz R, et al. ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. Blood Adv. 2026. PMID: 41949461. doi:10.1182/bloodadvances.2025019415
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。